HOW CAN WE HELP YOU? Call 1-800-TRY-CHOP
Abatacept Registry
This study is now recruiting.
The purpose of this registry is to study the long-term effects and safety of Abatacept(Orencia) as used for the treatment of Juvenile Idiopathic Arthritis(JIA). JIA patients that are currently taking Abatacept may be eligible to participate in this study.
Who Do I Contact?
If you are interested in participating in the study or want to learn more please contact our study team at rrc [at] chop.edu or 267-426-8726.
Eligibility & Criteria
IRB #:
17-013887
Official Title:
An Observational Registry of Abatacept in Patients with Juvenile Idiopathic Arthritis
Study Phase:
Not Applicable
Eligible Age Range:
0 - 18 Years
Gender:
All
Study Categories:
Leader
